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The bioengineered tissue plasminogen activator tenecteplase is an important treatment
modality of acute myocardial infarction recommended by international guidelines. Fol-
lowing introduction of originator tenecteplase (brand names Metalyse® and TNKase®),
a “biosimilar” tenecteplase became available for commercial use in India under the brand
name Elaxim® in the absence of Indian biosimilar guidelines which came into force from
September 15th, 2012. Based on a report of biochemical and ﬁbrinolytical differences
between Metalyse and Elaxim, we have systematically compared them in a range of
routine quality testing assays. As compared to Metalyse, Elaxim exhibited less clot lysis
activity and contained less of the two-chain form of tenecteplase. Even upon full in vitro
conversion to the two-chain form Elaxim exhibited less clot lysis activity. This was linked
to differences in sialic acid content and glycosylation pattern with Elaxim exhibiting less
bi- and more tetra-antennary glycosylation, leading to a different charge heterogeneity
proﬁle. Regarding purity, Elaxim contained more tenecteplase aggregates and, in contrast
to Metalyse, considerable amounts of Chinese hamster ovary cell protein. Taken together
these data demonstrate that Metalyse and Elaxim differ considerably in clot lysis activity
and biochemical properties.These data question whether Elaxim indeed can be considered
a “biosimilar” of Metalyse, i.e., whether and to which extent the clinical efﬁcacy and safety
properties of Metalyse can be extrapolated to Elaxim in the absence of comparative clinical
data.
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INTRODUCTION
Acute myocardial infarction is a leading cause of heart failure and
premature death (Kunadian and Gibson, 2012). In those who sur-
vive the acute phase, it may pose a ﬁnancial catastrophe due to
high out-of-pocket expenditures for acute cardiovascular care in
countries lacking a comprehensive health insurance system, e.g.,
India (Mohanan et al., 2013). The acute treatment aims for early
re-perfusion, preferably by primary percutaneous coronary inter-
vention (Steg et al., 2012), but this may not be feasible due to a
lack of early access to qualiﬁed facilities, e.g., in rural areas and
in emerging market countries. The alternative treatment is ﬁb-
rinolysis (Kunadian and Gibson, 2012). When performed within
6 h after symptom onset, ﬁbrinolytic therapy prevents approxi-
mately 30 early deaths per 1000 treated patients with ST Elevation
in Myocardial Infarction (Steg et al., 2012).
The serine protease tissue plasminogen activator (t-PA) is a
physiologically occurring 527 amino acid glycoprotein and the
main endogenous mediator of clot lysis. Its recombinant version
rt-PA (alteplase) has become the standard ﬁbrinolysis treatment in
patients with acute myocardial infarction, pulmonary embolism,
and acute ischemic stroke. The structure of t-PA is characterized
by ﬁve regions with homology to other protein families, i.e., a
ﬁnger, an epidermal growth factor-like, two kringle and a serine
protease domain. In contrast to classic zymogens, the intact one-
chain form of t-PA is already active in in vitro clot lysis assays, but
full activity is obtained by cleavage between amino acids 275 and
276 to the two-chain form.
Tenecteplase has been modiﬁed from rt-PA (alteplase) by sub-
stitution of threonine 103 with asparagine, asparagine 117 with
glutamine and a tetra-alanine substitution in position 296–299
(Davydov and Cheng, 2001). The mutation in position 103 cre-
ated a new glycosylation site, hereby enlarging the molecule and
increasing its half-life. The one in position 117 eliminated a
high mannose-type side chain, which also contributed to pro-
longing the half-life. The one in positions 296–299 increased
resistance to plasminogen activator inhibitor-1 (PAI-1). In com-
parison to rt-PA the combination of all three mutations resulted
in an extended half-life (18 vs. 4 min), higher ﬁbrin speci-
ﬁcity (14-fold) and increased resistance towards PAI-1 (80-fold;
Stewart et al., 2000; Davydov and Cheng, 2001). Accordingly,
tenecteplase is the ﬁrst and only therapeutic which can be used
as a single dose bolus application during the early stages of an
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acute myocardial infarction (Llevadot et al., 2001; Melandri et al.,
2009).
Similar to t-PA (Pohl et al., 1984), tenecteplase exhibits type
I and II glycoforms; type I has three carbohydrate structures at
asparagine residues 103, 184, and 448 (also termed glycosylation
sites 1, 2, and 3 and located in the kringle 1, kringle 2, and pro-
tease domain, respectively), whereas type II lacks the carbohydrate
at asparagine 184 (Parekh et al., 1989b). In contrast to alteplase,
however, all carbohydrates in tenecteplase are complex oligosac-
charides and no mannose structure is present, which prevents
clearance by the hepatic mannose receptor that has been observed
with alteplase (Tanswell et al., 2002). Of note, the speciﬁc glyco-
sylation pattern depends on the host organism for expression of
the genetically modiﬁed product and on other speciﬁc aspects of
the manufacturing process (Schellekens, 2009); changes in glyco-
sylation pattern can affect the ability of t-PA and tenecteplase to
activate plasminogen (Parekh et al., 1989a).
Tenecteplase was introduced globally into medical practice in
1999–2000 under the brand names TNKase® (Roche/Genentech,
South San Francisco, CA, USA) and Metalyse® (Boehringer Ingel-
heim Pharma GmbH & Co. KG, Ingelheim, Germany). Its efﬁcacy
and safety in the treatment of acute myocardial infarction has
been documented in numerous randomized controlled clinical
studies in which more than 15,000 patients received tenecteplase
(Llevadot et al., 2001; Kunadian and Gibson, 2012). A“biosimilar”
tenecteplase became available for commercial use in India under
the brand name Elaxim® (Gennova Pharmaceuticals Ltd., Hinjew-
adi, Pune, India); it is also available in some other Asian countries.
The only publicly available data on its efﬁcacy and safety in the
treatment of myocardial infarction come from an open label reg-
istry (Iyengar et al., 2011, 2013), which unfortunately lacks a clear
deﬁnition and validation of the reported outcomes. The present
study was designed to compare the clot lysis activity, purity, and
glycosylation status of originator tenecteplase and its purported
“biosimilar” variant.
MATERIALS AND METHODS
All testing was performed by using International Conference on
Harmonisation of Technical Requirements for Registration of
Pharmaceuticals for Human Use validated methods according to
standard operating procedures which are applied to the routine
quality control testing of tenecteplase batches within Boehringer
Ingelheim prior to release for market. An overview of method val-
idation (intermediate precision) is given in Table 1. Testing was
supplemented by state-of-the-art mass spectrometry analysis.
CHEMICALS
Commercial Metalyse lot#22579 was used as comparator which is
a representative lot for the highly consistent manufacturing pro-
cess. In comparison two lots of commercial Elaxim (#140903 and
#140904E04) were obtained from an Indian pharmacy. Throm-
bin, plasminogen, ﬁbrinogen, and sialidase were obtained from
Calbiochem (Merck, Darmstadt, Germany), respectively.
IN VITRO CLOT LYSIS
Clot lysis was determined by an automated ACL TOP® hemostasis
testing system (Instrumentation Laboratory, Bedford, MA, USA),
Table 1 | Method validation for Boehringer Ingelheim Metalyse release
tests.
Test method Intermediate precision coefficient
of variation (%)
Clot lysis activity assay 2
Chain composition by HP-SEC 1
Purity (monomer) by HP-SEC 1
Host cell proteins by CHOP ELISA 24
Type I/II by RP-HPLC 1
in which the lysing effect is measured as a decrease of turbidity.
Brieﬂy, standard (5 concentrations, 400–1200 ng/ml) or multiple
dilutions of tenecteplase were pipetted into sample cups (20 μl),
thrombin solution (20 μl) was added and then the reaction was
started by addition of a freshly mixed plasminogen/ﬁbrinogen
solution (200μl) at 37◦C.Themeasured lysis timewas thenplotted
against tenecteplase concentration on a double-logarithmic scale.
Enzyme activity was expressed as % of that of reference standard
as assessed within the same experiment.
CHAIN COMPOSITION
High-performance size-exclusion chromatography (HP-SEC) was
used to quantify the one- and two-chain forms of tenecteplase.
After reducing the disulﬁde bonds with dithiothreitol (DTT),
the one-chain material was separated from the two-chain mate-
rial based on its larger molecular weight and size. Analysis was
monitored at 210 nm using a size-exclusion chromatography
(SEC) column with a guard column (Tosoh Bioscience, Stuttgart,
Germany) and sodium dodecyl sulfate (SDS)/sodium phosphate
buffer as the mobile phase.
PURITY ANALYSIS
HP-SEC
Tenecteplase aggregates, monomers as well as smaller cleavage
products were separated by HP-SEC using a SEC column with
a guard column (Tosoh Bioscience, Stuttgart, Germany). Analysis
wasmonitored at 280 nm.An isopropanol/L-arginine/ammonium
sulfate buffer was used as mobile phase.
SDS-PAGE (silver staining)
Tenecteplase samples were separated by SDS polyacrylamide gel
electrophoresis (8–16% tris-glycine gels, constant current of
36 mA) under reducing conditions (sample buffer containing
160 mmol/l DTT). Thereafter, silver staining was performed by
a modiﬁed Oakley method (Oakley et al., 1980).
Host cell proteins
Host cell proteins are process related impurities originating from
the host cells used for manufacturing. The quantiﬁcation of host
cell protein, Chinese hamster ovary cell protein (CHOP), was
performed by a product-speciﬁc enzyme-linked immunosorbent
assay (ELISA) method on microtiter plates using a polyclonal
CHOP antibody (goat anti-CHOP, prepared in-house). A poly-
clonal, horseradish peroxidase-coupled antibody was used with
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ﬂuorescence detection of absorption at 490 nm and reference sig-
nal at 405 nm. Fluorescence signals were converted to units, with
1 U corresponding to 1 ng of CHOP standard.
Type I/Type II DETERMINATION
Reverse-phase high-performance liquid chromatography (RP-
HPLC) was used for the quantitation of the relative abundance
of Type I and Type II forms. Type I has all 3 N-glycosylation sites
occupied whereas the Type II form of tenecteplase has only two
N-glycosylation sites occupied (kringle 1 and protease domain).
Samples were treatedwith plasminogen to convert the tenecteplase
completely into the two-chain form. The samples were then
reduced with DTT to release the protease domain from the rest
of the molecule composed of ﬁnger, epidermal growth factor-
like, kringle 1, and kringle 2 domains, which were then separated
by RP-HPLC. The method separates molecules on the basis of
hydrophobicity. Theparameters for the separation are anon-linear
gradient with the buffer-systemof triﬂuoroacetic acid and puriﬁed
water as buffer A and triﬂuoroacetic acid and acetonitrile as buffer
B. Protein absorption was monitored at 214 nm. For tenecteplase
themore hydrophobic Type I elutes earlier than the Type II and the
C-terminal portion of the tenecteplase (protease domain) elutes in
the wash step of the acetonitrile gradient. Quantitation of Type I
tenecteplase was achieved by determining the percent Type I peak
area relative to the total Type I and Type II peak areas.
GLYCOSYLATION, SIALYLATION, BRANCHING
In order to characterize and quantify complex N-linked oligosac-
charides, assessed as the relative abundance of sialylated and
non-sialylated bi-, tri- and tetra antennary complex N-linked
oligosaccharides, AspN digested samples of Metalyse and Elaxim
were analyzed by RP-HPLC coupled to electrospray ioniza-
tion mass spectrometry. Brieﬂy, samples were denatured using
guanidine-HCl, reduced by DTT and alkylated with iodoacetic
acid. Reduced and alkylated samples were subsequently digested
using AspN (Roche, Mannheim, Germany). Resulting peptides
were separated by RP-HPLC (C18-column) coupled with an ESI-
Q-TOF premier mass spectrometer (Waters, Eschborn,Germany).
MassLynx was used as data evaluation software. Separation of
AspN peptides was achieved using an increasing acetonitrile elu-
tion gradient from 2% of mobile phase B (85% of acetonitrile
in water, 0.1% of triﬂuoroacetic acid) to 45% of mobile phase B
in 120 min. After the RP-HPLC run was completed and all pep-
tides were eluted, the full-scan total ion current chromatogram
was extracted for the corresponding high resolution masses of the
glycopeptides as selective ion chromatogram for each of the three
N-linked glycosylation sites [glycopeptide 1 (kringle 1): DQGI-
SYRGNWSTAESGAECTNWQSSALAQKPYSGRRP; glycopeptide
2 (kringle 2): DCYFGNGSAYRGTHSLTESGASCLPWNSMILIG-
KVYTAQNPSAQALGLGKHNYCRNP; glycopeptide 3 (protease
domain): DWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSR-
CTSQHLLNRTV (the glycosylation site is underlined)]. For each
glycosylation site the summarized signal intensities of the related
mass/charges (m/z) of the selected ion chromatograms of the gly-
copeptides were integrated and summarized to 100% and then
the ratio was calculated for sialylated and non-sialylated bi-, tri-
and tetra-antennary complex N-linked oligosaccharides. Based on
these data the degree of sialylation for each glycosylation site was
calculated as follows: sialylation = [ mono-sialylated structures
(%) + 2 x  bi-sialylated structures (%) + 3 x  tri-sialylated
structures (%) + 4 x  tetra-sialylated structures (%)]. As gly-
copeptide 2 is not fully occupied, a correction for site occupancy
was performed. Total sialylation was calculated as the sum of the
three individual sialylations and expressed as either mol/mol or
% values relative to Metalyse® reference standard. The degree of
free terminal hexoses was determined after removal of sialic acid
residues using sialidase, analogously as described above for total
sialylation.
ISOELECTRIC FOCUSING
To determine the charge heterogeneity of tenecteplase as a result
of different branching and sialylation, isoelectric focusing was
performed using a Phast system and PhastGels IEF 5–8 (GE
Healthcare, Freiburg, Germany). PhastGels IEF 5–8 were equi-
librated and run according to the manufacturer’s instructions.
After focusing, the gels were stained using Coomassie G250 by
a modiﬁed method according to Neuhoff et al. (1985).
STATISTICAL ANALYSIS
Our study is based on highly standardized and well validated qual-
ity control release assays. Across all quantitative assays both tested
Elaximbatches consistently differed from the representativeMetal-
yse batch to a degree which considerably exceeds the precision
of the respective method (Table 1). Therefore, experiments were
not repeated multiple times, and hence statistical analysis was not
performed.
RESULTS
IN VITRO CLOT LYSIS
For each tested concentration, the twobatches of Elaxim required a
longer time to cause lysis than the tenecteplase reference standard,
whereas lysis time of Metalyse matched values from the reference
standard (Figure 1). From these ﬁndings tenecteplase activities of
77% and 76% for Elaxim #140903 and #140904E04, respectively,
were determined as compared to 97% for Metalyse (Figure 1). A
lower biological activity of the two lots of Elaxim (72–78%) was
conﬁrmed in two other assays, i.e., the activity assay performed
using an alternative quality control assay and the clot lysis activity
method described in the European Pharmacopoeia monograph
on alteplase, where Metalyse exhibited activities of 99–100% (data
not shown).
CHAIN COMPOSITION AND IN VITRO CHAIN CONVERSION
The two-chain form is the most active form of tenecteplase. In
conﬁrmation of previous studies (Jiang et al., 2010), the relative
abundance of the two-chain form in the two Elaxim batches was
only about half that of Metalyse (Figure 2). After in vitro enzymatic
conversion of tenecteplase yielding 95–97% two-chain form for
both tested batches, clot lysis activity was determined and found
to be lower for the two Elaxim batches as compared to Metalyse
(Figure 2).
PURITY ANALYSIS
Three types of experiments were performed for purity analy-
sis. Firstly, in the SEC assay, 98.4% of Metalyse was found
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FIGURE 1 | In vitro clot lysis by one batch of Metalyse and two
batches of Elaxim. (A) Raw data for the time course of turbidity change
induced by 400, 600, 800, 1000, and 1200 ng/ml tenecteplase reference
standard. (B–D) Double-logarithmic plot of clot lysis time vs. concentration
of test compound in comparison to matched tenecteplase reference
standard. Based on these data the calculated in vitro clot lysis activity for
Metalyse was 97% as compared to 77 and 76% for the two batches of
Elaxim.
as monomer, 1.0% as aggregates and 0.6% as fragments. In
contrast, both Elaxim lots #140903 and #140904E04 contained
only 96.4% monomers but 2.9% aggregates and 0.4% frag-
ments. Secondly, in SDS polyacrylamide gel electrophoresis
experiments under reducing conditions and with silver stain-
ing detection, Elaxim lots #140903 and #140904E04 exhib-
ited high molecular weight impurities (Figure 3). Thirdly,
in the ELISA testing for presence of CHOP, Elaxim batches
#140903 and #140904E04 yielded 6590 and 6990 U, respec-
tively, whereas Metalyse yielded < 15 U (the lower limit of
quantiﬁcation).
GLYCOSYLATION, SIALYLATION, AND BRANCHING
In RP-HPLC experiments, the relative abundance of type I
tenecteplase was 42% for Metalyse as compared to 37% and 34%
for Elaxim batches #140903 and #140904E04, respectively.
Glycosylation was analyzed by mass spectrometry (RP-HPLC-
ESI-MS); Figure 4 shows examples of the deconvoluted spectra
for Metalyse and Elaxim lots #140903 and #140904E04 for the
glycopeptide 2 (kringle 2). Both Elaxim lots exhibited a lower
percentage of bi-non-sialylated N-linked oligosaccharides at gly-
cosylation site 1 as compared to Metalyse, whereas tri- and
tetra-sialylated glycosylation was observed with both Elaxim lots
but not with Metalyse (Figure 5), indicating a higher degree
of tri- and tetra-antennary branching at glycosylation site 1 in
kringle 1. At glycosylation sites 2 and 3, the Elaxim batches also
inhibited less bi- and more tetra-antennary N-linked oligosaccha-
rides than Metalyse (Figure 5). Accordingly, combined data for
all three glycosylation sites indicated reduced bi- and increased
tetra-antennary glycosylation in Elaxim as compared to Metalyse
(Figure 5). To corroborate these ﬁndings the total sialylation and
free terminal hexose content after removal of sialic acid residues
of the tested tenecteplase preparations was determined. Metalyse,
Elaxim batch #140903, and Elaxim batch #140904E04 had 3.6, 5.0,
and 5.0 mol sialic acid/mol tenecteplase, respectively, correspond-
ing to 98, 130, and 136% of reference standard, respectively. Free
terminal hexoses after removal of sialic acid measurement resulted
in 5.5, 6.2, and 6.3 mol free hexose per mol tenecteplase for Metal-
yse and Elaxim lots #140903 and #140904E04, respectively. There
is a fourth O-linked fucose glycosylation site at position threonine
61 in the EGF domain, for which comparable results (fully glyco-
sylated) was found for both Metalyse and the two Elaxim batches
(data not shown), which is in line with published data (Jiang et al.,
2010).
Finally isoelectric focusing was used to determine the charge
heterogeneity. This demonstrated a shift to the acidic region for
both Elaxim lots yielding an overall pattern distinct from that of
Metalyse (Figure 6).
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FIGURE 2 | Relative abundance of one- and two-chain form (upper
panel) and in vitro clot lysis activity of Elaxim and Metalyse
enzymatically converted to two-chain form (lower panel).
DISCUSSION
A pharmaceutical product is considered a biosimilar if it is
highly similar to an already approved biological product, notwith-
standing minor differences in clinically inactive components
(Schellekens, 2009). If similarity including purity is high, it is
assumed that the efﬁcacy and safety of the biosimilar can be
extrapolated from the originator drug. Based on this assumption,
biosimilars often receive regulatory approval based on more
limited experimental and clinical data packages than the origina-
tor biological agent. However, in contrast to traditional generics
and based on their more complex three-dimensional structures,
biosimilars are often more fragile physically and chemically,
and have more stringent formulation and storage requirements
than small molecule-based generic drugs (Kuhlmann and Marre,
2010).
Biosimilars are attractive from a public health perspective as
they typically are less expensive and hence can make treatment
FIGURE 3 | Silver staining of gel from SDS electrophoresis under
reducing conditions to detect tenecteplase aggregates and fragments.
Lanes: 1–2 bovine serum albumin staining control; 4 Elaxim #140903; 5
Elaxim #140904E04; 6 Metalyse; 8 reference standard; 11 molecular
weight markers. The right-facing arrows point to additional high molecular
weight impurities.
FIGURE 4 | Deconvoluted spectra of glycopeptide 2 (kringle 2) acquired
on an ESI-Q-TOF instrument, for Metalyse® lot #22579 and Elaxim lots
#140903 and #140904E04.
more affordable. However, in the interest of safe and efﬁcacious
treatment this consideration only applies if the biosimilar does
not exhibit clinically relevant differences to the originator product.
The veriﬁcation of similarity between the innovator biopharma-
ceutical and the biosimilar is amajor challenge, as protein products
generally exhibitmicroheterogeneities,whichmay affect biological
activity. Therefore, the present study was designed to compare the
“biosimilar” variant Elaxim to the innovator tenecteplase Metal-
yse in terms of activity and purity status in a range of quality
control assays, as well as glycosylation status analyzed by mass
spectrometry. Of note, all of the quantitative differences between
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FIGURE 5 | Relative abundance of bi-, tri- and tetra-antennary N-linked oligosaccharides (indicated as white, grey, and black bars, respectively) at
glycosylation sites in kringle 1, kringle 2, and protease domain and in the overall glycosylation sites.
representative lots of Metalyse and Elaxim reported here markedly
exceed the variance of the test methods being applied (Table 1).
Previous studies have demonstrated that Metalyse and Elaxim
do not differ in their primary amino acid sequence or the 17 intra-
molecular disulﬁde linkages (Jiang et al., 2010). The glycosylation
occupancy at asparagine 184, differentiating Type I and Type II
tenecteplase, was reported to be approximately 60% for Metalyse
as compared to 25% for Elaxim (Jiang et al., 2010). As changes
in glycosylation affect the ability of t-PA and tenecteplase to acti-
vate plasminogen (Parekh et al., 1989a), we ﬁrst compared the
functional relevance of such glycosylation differences on clot lysis
activity. Unlike the expectation that a lower degree of glycosyla-
tion at asparagine 184 is linked with higher clot lysis activity, the
clot lysis activity of Elaxim was only 72–78% of the reference stan-
dard as compared to 99–100% for Metalyse; this lower biological
activity of Elaxim was consistent across two batches of Elaxim and
three distinct assays. Considering the intermediate precision of
the clot lysis activity assay (Table 1), these data demonstrate that
the biological activity of Elaxim differs from that of Metalyse. Our
subsequent experiments were designed to explore the reasons for
this difference.
As the two-chain form is the most active form of tenecteplase,
we have compared the one- vs. two-chain content of Metalyse
and Elaxim. In conﬁrmation of data from other investigators
(Jiang et al., 2010), we found a lower two-chain content in two
Elaxim batches as compared with Metalyse. Jiang et al. (2010) had
argued that “any single-chain form should convert into the two-
chain forms on contact with plasma” and hence such difference
should contribute little to differences in biological activity. Rather
they proposed that consistency of the % of two-chain produc-
tion should be a gauge of the manufacturer’s reproducibility. Our
experiments extend this line of thinking by demonstrating that
even upon full in vitro conversion to the two-chain form, two
batches of Elaxim consistently exhibited less clot lysis activity than
Metalyse, indicating possible molecule-intrinsic differences (see
next paragraph).
Our data with tenecteplase fully converted to the two-chain
form indicate that Elaxim may exhibit intrinsically less clot lysis
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FIGURE 6 |Tenecteplase charge heterogeneity as detected by
isoelectric focusing. Lanes left panel: 2 reference standard; 3 Metalyse;
4 Elaxim #140904E04; 5 pl-marker. Lanes right panel: 2 pl-marker; 3
reference standard; 4 Metalyse; 5 Elaxim #140903; 6 pl-marker. Arrows
indicate shift of bands to the acidic region as compared to reference
standards.
activity than Metalyse. As both tenecteplase products do not differ
in their primary amino acid sequence or the 17 intra-molecular
disulﬁde linkages (Jiang et al., 2010), a difference in glycosylation
pattern of the polypeptide may contribute. Of note, glycosylation
patterns are not only dependent on primary amino acid sequence
but also on the particular cell type used for expression of the
recombinant polypeptide in the manufacturing process. t-PA con-
tains three potential N-glycosylation sites, of which either three
(Type I) or two (Type II) are occupied (Pohl et al., 1984). In our
HPLC experiments, the relative abundance of Type I was 42%
for Metalyse as compared to 34–37% for the two Elaxim batches.
As Type II tenecteplase is considered to be more active (Parekh
et al., 1989a), the lower percentage of Type I would suggest that
Elaxim has greater clot lysis activity, but the opposite was found.
This could be linked to its greater single-chain content and/or to
difference in glycosylation. Moreover, oxidation of t-PA has been
proposed to reduce ﬁbrin binding and clot lysis activity (Stief et al.,
1991), and the relative percentage of oxidation at methionine 207,
445, and 490 was higher with Elaxim than with Metalyse (Jiang
et al., 2010).
This prompted us to explore the glycosylation patterns of
Elaxim and Metalyse in more detail. At each of the three inves-
tigated N-linked glycosylation sites, i.e., kringle 1, kringle 2,
and protease domain, the two Elaxim batches exhibited a dif-
ferent relative abundance of bi-, tri- and tetra-antennary N-linked
oligosaccharides, yielding an overall glycosylation patternwith less
bi- and more tetra-antennary glycosylation. This was conﬁrmed
by quantiﬁcation of free terminal hexoses after removal of sialic
acid. Based on the known relationship between glycosylation site
occupancy and biological activity in the clot lysis assay (Jiang et al.,
2010), these differences in glycosylation patternwould suggest that
the higher branching (more tetra-antennary N-linked oligosac-
charides), as well as the higher total sialylation may contribute to
a decreased clot lysis activity of Elaxim.
To explain lower clot lysis activity of Elaxim, found to be
smaller even after full conversion to the two-chain form, three
types of experiments were performed to test whether possibly
contributing impurities also are present. These demonstrated a
higher fraction of fragments in two Elaxim batches than in Metal-
yse. Moreover, electrophoresis with silver staining detected higher
molecularweight impurities inElaximwhichwere absent inMetal-
yse. Finally, an ELISA detected substantial amounts of CHOP in
both Elaxim batches which were below the quantiﬁcation limit
in Metalyse. Thus, three direct assays demonstrated that Elaxim
exhibited a greater degree of impurities than Metalyse. These ﬁnd-
ings substantiate the proposal by Jiang et al. (2010) with regard to
manufacturing reproducibility of Elaxim.
In summary, previous (Jiang et al., 2010) and present data
demonstrate that Elaxim has less clot lysis activity than Metal-
yse. This was linked to a lower abundance of the two-chain
form, a quantitatively different glycosylation pattern leading to
a different charge heterogeneity proﬁle and a greater methion-
ine oxidation. Moreover, the tested Elaxim batches exhibited a
greater percentage of tenecteplase aggregates as well as contami-
nation with host cell protein. For some of these parameters there
was also inconsistency between the tested Elaxim batches. It is
possible that these biochemical differences may also contribute
to differential storage requirements, i.e., according to the respec-
tive prescribing information Elaxim needs to be stored under
refrigeration at 2–8◦C whereas an unopened vial of Metalyse
can be stored at up to 30◦C. These ﬁndings suggest that Elaxim
may not be a “biosimilar” to Metalyse according to internation-
ally accepted standards. Hence, the reported differences between
the two types of tenecteplase may translate into differences in
efﬁcacy and safety and it does not appear justiﬁed to extrapo-
late and apply the extensive data from clinical Metalyse studies
(Llevadot et al., 2001; Melandri et al., 2009) to Elaxim. In view of
differences in the structure, impurities, and related ﬁbrinolytic
activity as compared to Metalyse, extensive dedicated non-clinical
and randomized controlled clinical studies are required to char-
acterize the efﬁcacy and safety proﬁle of Elaxim in order to
unequivocally deﬁne its place in the treatment of acute myocardial
infarction.
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